Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112418 · ClinicalTrials.gov registry record · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
A NA study of Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by Cleerly.
- Recruiting
- Registry status
- NA
- Development phase
- 7,500
- Enrollment target
- 20
- Study locations
NCT06112418: Recruiting NA study of Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by Cleerly.
NCT06112418 is a NA study of Diabetes Mellitus, Type 2 and PreDiabetes that is actively recruiting participants, run by Cleerly. The registered enrollment target is 7,500 participants, above the 4,464-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06112418, a NA study of Diabetes Mellitus, Type 2 and PreDiabetes, is actively recruiting participants, sponsored by Cleerly.
- RECRUITING
- Registry status
- NA
- Development phase
- 7,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Primary Outcome
The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure.
Conditions Studied
Interventions
- DEVICE The Cleerly CAD Staging System
Study Locations (20)
California
- Cardiovascular Research Foundation of Southern California - Beverly Hills
- Amicis Research: Beverly Hills - Beverly Hills
- Valiance Clinical Research - Canoga Park - Canoga Park
- Cardiovascular Institute of San Diego - Chula Vista
- Amicis Research: Granada Hills - Granada Hills
- Valiance Clinical Research: Huntington Park - Huntington Park
- HALO Diagnostics - Indian Wells
- Scripps Health - La Jolla
- Chemidox Clinical Trials - Lancaster
- Long Beach Research Institute - Long Beach
- Ace Research Institute - Monterey Park - Monterey Park
- Amicis Research: Newhall - Newhall
- Ace Research Institute: Northridge - Northridge
- Amicis Research: Northridge - Northridge
- Ace Research Institute: Northridge #2 - Northridge
- Northridge Clinical Trials - Northridge
Arizona
- Chandler Clinical Trials - Chandler
- Scottsdale Clinical Trials - Scottsdale
- Sun City Research - Sun City
- Noble Clinical Research - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,500 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2029-03-05 |
| Phase | NA |
What NCT06112418 shows while recruiting
NCT06112418 is an interventional study that assigns participants to a tested intervention. Its 7,500 participants enrollment target places it among the larger protocols in the corpus, above the 4,464-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (68% higher).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which The Cleerly CAD Staging System is the first listed.
NCT06112418 names 20 study sites across 2 states, led by California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06112418 about?
NCT06112418 is a clinical study titled "A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events". TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (...
What is the current status of trial NCT06112418?
This trial is currently recruiting. It is a NA study. The enrollment target is 7,500 participants. The study started on 2024-03-06. Estimated completion is 2029-03-05.
What conditions does trial NCT06112418 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome.
What interventions are being tested in trial NCT06112418?
The interventions under investigation include: The Cleerly CAD Staging System (DEVICE).
Who is sponsoring clinical trial NCT06112418?
This trial is sponsored by Cleerly, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112418 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06112418's enrollment target sits among peer trials
7,500 15th of 348 higher than 334 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI